Important note: Information in this article was accurate in February 2003. The state of the art may have changed since the publication date.  |
IAVI Report - February / April 2003
New Members for IAVI SAC, Board
In January 2003, Ian Gust took over from Jaap Goudsmit as chair of IAVI's Scientific Advisory Committee (SAC), which helps guides ongoing projects and future initiatives. The SAC is composed of 12 experts in AIDS vaccine development and related fields, and has three sub-committees: Vaccine science, project management and clinical trials.
Gust has been on IAVI's SAC since it began in 1997. An MD and medical virologist, he directed the WHO Collaborating Centre for Virus Reference and Research for 18 years, and presently sits on the WHO Expert Panel on Virus Diseases. Gust is a professorial fellow in Microbiology and Immunology at the University of Melbourne and non-executive director of an Australian biotech company, Biota.
There have also been changes to IAVI's Board of Directors. Geoffrey Lamb, Vice President of Resource Mobilization and Co-financing at the World Bank, has taken over from Lee Smith as chair. Lamb is also a board member of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Other new Board members, replacing those whose three-year terms have finished, are: Awa Coll-Seck (Minister of Health and Prevention, Senegal), Chrispus Kiyonga (Chairperson, Global Fund to Fight AIDS, Tuberculosis, and Malaria), Kapil Sibal (Member of Parliament, India), Paul Klingenstein (general partner and founder of Aberdare Ventures, a venture capital company) and Ian Gust, representing IAVI's SAC. A complete list of SAC and Board members is available at www.iavi.org/about/
IAVI Core Immunology Lab Up and Running
IAVI's Core Immunology lab, based at the Chelsea and Westminster Hospital in London and run by Frances Gotch, is now fully functional. Its present activities are centered around analyzing samples from ongoing IAVI vaccine trials and providing training for African and European laboratory staff.
In November, the lab sponsored a three-day course in good clinical laboratory practice (GCLP) for staff of current and future trials. Participants included researchers from the core lab, the Oxford UK trial site, the Kenyan AIDS Vaccine Initiative and the Uganda Virus Research Institute—all of whom are involved with ongoing trials—along with others from Rwanda, South Africa and Sweden, where trials are planned. The course covered issues pertaining specifically to vaccine studies, including regulatory requirements, personnel organization in the lab, writing and adhering to standard operating procedures, sample handling, data management and accountability. The British Association of Research Quality Assurance led the course. A similar course is planned for April 2003, to include research teams from India and China.
The Core lab analyzes samples from the London trial site, in addition to selected samples previously analyzed in the field labs of all IAVI-sponsored vaccine trials. This head-to-head comparison of data provides quality control for the field labs and confirms that the data are valid and reproducible.
India Workshop looks at challenges around women and vaccine trials
On 22-23 November 2002, the IAVI India Team hosted a consultation on gender issues and HIV vaccine trials. The meeting's 25 participants included women's health advocates, representatives of NGOs, PLWHAs, public health policymakers, lawyers, ethicists, vaccine scientists, trial administrators, and researchers with experience in conducting other types of vaccine trials, particularly contraceptive trials.
In India, as in many other parts of the world, there may be special challenges to women's participation in vaccine trials. The discussion mapped out issues that could arise at all phases of vaccine development. In the past, community concerns have stopped, or severely delayed, problematic biomedical research in India. Participants agreed to continue working with IAVI to identify and address issues that could arise through vaccine testing.
The meeting generated several action steps, which will be pursued through the work of small advisory groups. Key issues include development and review of informed consent protocols; gender sensitization for all stakeholders involved in vaccine preparedness and testing; and community mobilization. The report-back from the meeting concluded that, "While the gender lens has to be focused on the needs of entire communities, families, and men, the realities of women and socially and economically vulnerable groups are to be kept in the foreground."
IAVI Appoints New Policy Advisory Committe
In February 2003, IAVI announced the establishment of a Policy Advisory Committee that will provide guidance to the organization as it expands its activities in both global advocacy and policy research.
Committee members have been drawn from academia, non-profit organizations and the private sector, and bring expertise in areas such as delivery systems for vaccines, introduction of new health care technologies, economics of vaccines, international financial mechanisms, regulatory issues and international development.
The committee members are:
030211
IAVI2003-0211
©2003. The IAVI Report.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
